Trials / Completed
CompletedNCT02223416
A Study Aimed at Assessing the Pharmacokinetic Properties of RGB-10 and Forsteo
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Gedeon Richter Plc. · Industry
- Sex
- Female
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
Pharmacokinetic properties, safety and tolerability of RGB-10 and Forsteo will be compared in healthy female volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RGB-10 | |
| DRUG | Teriparatide |
Timeline
- Primary completion
- 2015-01-01
- First posted
- 2014-08-22
- Last updated
- 2015-03-18
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT02223416. Inclusion in this directory is not an endorsement.